Bayhill Therapeutics

Bayhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for autoimmune diseases. The company leverages its therapeutic BHT-DNA platform to develop a pipeline of therapeutic candidates for autoimmune diseases. Its clinical products include BHT-3021, which is in Phase I/II clinical trials to reduce or eliminate immune system attacks on the pancreas; BHT-3009, which has completed Phase II trials for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.